One-Shot gene therapy tested for rare lung disease
NCT ID NCT06996756
Summary
This is an early safety study for a new gene therapy designed to treat Alpha-1 Antitrypsin Deficiency, a genetic condition that can cause serious lung disease. Researchers are testing a single injection that aims to help the body produce a protective protein long-term. The study will enroll 16 people with mild to moderate lung damage to find a safe dose and see if the treatment increases protein levels in the blood and lungs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
WCMC Department of Genetic Medicine
RECRUITINGNew York, New York, 10021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.